"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

John Michael DiBianco, MD, discusses findings from the BLUES trial. A recent study evaluated silicone vs polyurethane stents found that the primary outcome of pain intensity and interference at 7 to ...

Robotic prostate surgery and resource use: When prostate surgery is performed robotically, the patient typically requires a catheter for about 1 week. This leads to increased resource utilization, ...

Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for GSM. The recent release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of ...

Nearly 60% of patients taking vibegron remained on treatment at 1 year. The real-world, phase 4 COMPOSUR study (NCT05067478) found that nearly 60% of patients taking vibegron remained on treatment at ...